Patricia Sebastian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patricia Sebastian has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh Balakrishnan
Christian Medical College Vellore
6 shared publications - Krishna Prabhu
Department of Neurological Sciences, Christian Medical College, Vellore, India
3 shared publications - RanjithKrishna Moorthy
Department of Neurological Sciences, Christian Medical College, Vellore, Tamil Nadu, India.
3 shared publications - Rikki John
Department of Pediatric Hematology-Oncology, Christian Medical College, Vellore, India
3 shared publications Selvamani Backianathan
Christian Medical College Vellore
3 shared publications- Selvamani Backianathan
Department of Radiotherapy, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
3 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of Indian Association of Pediatric Surgeons
- Vol. 31  (3) , 449-455
Is There a Role for External Radiation Therapy in Pediatric Differentiated Thyroid Cancer?
A BSTRACT: Introduction: Pediatric differentiated thyroid carcinoma (DTC) has a higher incidence of locally advanced disease than adults. The efficacy of external beam radiation therapy (EBRT) prior to radioactive iodine ablation (RAIA) for inadequate resection and gross residual is established in adults, but not supported in children. Aim: The aim of this study was to evaluate the efficacy and toxicity in pediatric DTC patients who received EBRT prior to RAIA. Methodology: Data from November 2005 to November 2025 were retrospectively analyzed. Those who received EBRT to the neck prior to RAIA were included. The toxicity profile and response to RAIA were recorded. Results: A total of 112 children had DTC, of which 8 (3 females, 5 males, age range: 8â17 years, and mean: 12 years) were included. Six received conventional RT [40 Gy in 20 fractions followed by electron boost (16â20 Gy)]. Two received intensity-modulated radiation therapy (60â66 Gy). Total whole body scintigraphy scan (TWBS) showed residual disease in postoperative bed in 1, residual with lung metastases in 4, residual with nodal metastases in 2 and negative scan in 1 patient. Range of first stimulated serum thyroglobulin was 61-2400 ng/ml. Cumulative dose of RAIA ranged from 75 to 395 mCi. All showed significant biochemical and scintigraphic decrease. Response according to the American Thyroid Association (2025) was excellent in four, structurally incomplete in two and biochemically incomplete in two at the end of follow-up (median follow-up: 11.5 years and range: 1â23 years). Except for hypertrophic scar, none had significant patient-reported side effects. Conclusion: EBRT is a feasible adjuvant treatment option for selected pediatric DTC patients with locally aggressive disease â gross extrathyroidal extension or unresectable disease.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of Indian Association of Pediatric Surgeons
- Vol. 31  (3) , 449-455
Open AccessIs There a Role for External Radiation Therapy in Pediatric Differentiated Thyroid Cancer?
A BSTRACT: Introduction: Pediatric differentiated thyroid carcinoma (DTC) has a higher incidence of locally advanced disease than adults. The efficacy of external beam radiation therapy (EBRT) prior to radioactive iodine ablation (RAIA) for inadequate resection and gross residual is established in adults, but not supported in children. Aim: The aim of this study was to evaluate the efficacy and toxicity in pediatric DTC patients who received EBRT prior to RAIA. Methodology: Data from November 2005 to November 2025 were retrospectively analyzed. Those who received EBRT to the neck prior to RAIA were included. The toxicity profile and response to RAIA were recorded. Results: A total of 112 children had DTC, of which 8 (3 females, 5 males, age range: 8â17 years, and mean: 12 years) were included. Six received conventional RT [40 Gy in 20 fractions followed by electron boost (16â20 Gy)]. Two received intensity-modulated radiation therapy (60â66 Gy). Total whole body scintigraphy scan (TWBS) showed residual disease in postoperative bed in 1, residual with lung metastases in 4, residual with nodal metastases in 2 and negative scan in 1 patient. Range of first stimulated serum thyroglobulin was 61-2400 ng/ml. Cumulative dose of RAIA ranged from 75 to 395 mCi. All showed significant biochemical and scintigraphic decrease. Response according to the American Thyroid Association (2025) was excellent in four, structurally incomplete in two and biochemically incomplete in two at the end of follow-up (median follow-up: 11.5 years and range: 1â23 years). Except for hypertrophic scar, none had significant patient-reported side effects. Conclusion: EBRT is a feasible adjuvant treatment option for selected pediatric DTC patients with locally aggressive disease â gross extrathyroidal extension or unresectable disease.
- Open Access
- 11 December 2025
- Published by Wiley
Whispers in the Windpipe: Rare cases of Tracheal Plasmacytoma from a Tertiary Care Centre with Literature Review
- 11 December 2025
- Published by Wiley
Open AccessWhispers in the Windpipe: Rare cases of Tracheal Plasmacytoma from a Tertiary Care Centre with Literature Review
- 22 September 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72  (12) , e32056
Outcomes of Infant Medulloblastoma Treated With StandardâDose ChemotherapyâA SingleâInstitution Experience From a LowâMiddleâIncome Country
Background: Infant medulloblastoma (iMBL) is predominantly desmoplastic nodular (DN) or medulloblastoma with extensive nodularity (MBEN) histology, sonic hedgehog (SHH) driven. Intensified chemotherapy (intraventricular chemotherapy or highâdose chemotherapy with autologous stem cell rescue) is recommended to compensate for the omission of radiation. This study aims to analyze the outcomes of iMBL treated without treatment intensification. Methods: This retrospective study was performed on 28 patients with iMBL (children with medulloblastoma n = 6, 21%). Half of the cohort had nonmetastatic disease. Sixteen patients had DN/MBEN histology. Only 68% ( n = 19) opted to continue postoperative treatment. Chemotherapy protocols used were baby SFOP, HIT SKK, and modified Packer. One fourth ( n = 7) received radiation (DN/MBEN = 3; other histology = 4) as a part of their initial treatment. There was no treatmentârelated mortality. The 5âyear eventâfree survival (EFS) of patients who received postoperative chemotherapy Âą RT was 70% (those with DN/MBEN were 82.5% and nonâDN/MBEN were 35.7%). The 5âyear EFS of patients with DN/MBEN histology who received only chemotherapy ( n = 9) was 88.9%. Conclusions: Managing medulloblastoma in infants is challenging in LMIC, as a significant proportion of families opt against postoperative treatment. Although traditionally considered high risk, good survival can be achieved with nonâintensified therapy without an increase in treatmentârelated mortality, especially in patients with DN/MBEN histology.
- 22 September 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72  (12) , e32056
Outcomes of Infant Medulloblastoma Treated With StandardâDose ChemotherapyâA SingleâInstitution Experience From a LowâMiddleâIncome Country
Background: Infant medulloblastoma (iMBL) is predominantly desmoplastic nodular (DN) or medulloblastoma with extensive nodularity (MBEN) histology, sonic hedgehog (SHH) driven. Intensified chemotherapy (intraventricular chemotherapy or highâdose chemotherapy with autologous stem cell rescue) is recommended to compensate for the omission of radiation. This study aims to analyze the outcomes of iMBL treated without treatment intensification. Methods: This retrospective study was performed on 28 patients with iMBL (children with medulloblastoma n = 6, 21%). Half of the cohort had nonmetastatic disease. Sixteen patients had DN/MBEN histology. Only 68% ( n = 19) opted to continue postoperative treatment. Chemotherapy protocols used were baby SFOP, HIT SKK, and modified Packer. One fourth ( n = 7) received radiation (DN/MBEN = 3; other histology = 4) as a part of their initial treatment. There was no treatmentârelated mortality. The 5âyear eventâfree survival (EFS) of patients who received postoperative chemotherapy Âą RT was 70% (those with DN/MBEN were 82.5% and nonâDN/MBEN were 35.7%). The 5âyear EFS of patients with DN/MBEN histology who received only chemotherapy ( n = 9) was 88.9%. Conclusions: Managing medulloblastoma in infants is challenging in LMIC, as a significant proportion of families opt against postoperative treatment. Although traditionally considered high risk, good survival can be achieved with nonâintensified therapy without an increase in treatmentârelated mortality, especially in patients with DN/MBEN histology.
- Open Access
- 16 April 2025
- Published by Wiley
Outcomes of infant medulloblastoma treated with standard dose chemotherapy-A single institutional experience from a Low middle income country
Background Infant medulloblastoma (iMBL) are predominantly desmoplastic nodular (DN) or Medulloblastoma with Extensive Nodularity (MBEN) histology, Sonic Hedgehog (SHH) driven. Intensified chemotherapy (intraventricular chemotherapy or high-dose chemotherapy with autologous stem cell rescue) is recommended to compensate the omission of radiation. This study aims to analyse the outcomes of iMBL treated without treatment intensification. Methods This retrospective study was done on 28 patients with iMBL (children with medulloblastoma Results The median age at diagnosis and duration of symptoms were 24.5 months and 1 month, respectively. Vomiting (82%) and ataxia (71.4%) were the common presentations. Ventriculoperitoneal shunt or endoscopic 3 rd ventriculostomy was done in 57% patients. Twenty-four patients (~86%) underwent gross/near total resection. The most common surgical complication was cerebellar mutism (n=6, 21%). Half of the cohort had non-metastatic disease. Sixteen patients had DN/MBEN histology. Only 68%(n=19) opted to continue adjuvant therapy. Chemotherapy protocols used were Baby SFOP, HIT SKK and modified Packers. One fourth (n=7) received radiation (DN/MBEN=3, other histology=4) after 3 years of age. There was no treatment related mortality. The 5-year EFS of patients who received adjuvant treatment, DN/MBEN, non-DN/MBEN histology were 70%, 82.5% and 35.7%, respectively. Conclusions Managing medulloblastoma in infants is challenging in LMIC as significant proportion of families opt against adjuvant treatment. Although traditionally iMBL considered high risk, good outcomes can be achieved with non-intensified therapy in DN/MBEN subgroup.
- 16 April 2025
- Published by Wiley
Open AccessOutcomes of infant medulloblastoma treated with standard dose chemotherapy-A single institutional experience from a Low middle income country
Background Infant medulloblastoma (iMBL) are predominantly desmoplastic nodular (DN) or Medulloblastoma with Extensive Nodularity (MBEN) histology, Sonic Hedgehog (SHH) driven. Intensified chemotherapy (intraventricular chemotherapy or high-dose chemotherapy with autologous stem cell rescue) is recommended to compensate the omission of radiation. This study aims to analyse the outcomes of iMBL treated without treatment intensification. Methods This retrospective study was done on 28 patients with iMBL (children with medulloblastoma Results The median age at diagnosis and duration of symptoms were 24.5 months and 1 month, respectively. Vomiting (82%) and ataxia (71.4%) were the common presentations. Ventriculoperitoneal shunt or endoscopic 3 rd ventriculostomy was done in 57% patients. Twenty-four patients (~86%) underwent gross/near total resection. The most common surgical complication was cerebellar mutism (n=6, 21%). Half of the cohort had non-metastatic disease. Sixteen patients had DN/MBEN histology. Only 68%(n=19) opted to continue adjuvant therapy. Chemotherapy protocols used were Baby SFOP, HIT SKK and modified Packers. One fourth (n=7) received radiation (DN/MBEN=3, other histology=4) after 3 years of age. There was no treatment related mortality. The 5-year EFS of patients who received adjuvant treatment, DN/MBEN, non-DN/MBEN histology were 70%, 82.5% and 35.7%, respectively. Conclusions Managing medulloblastoma in infants is challenging in LMIC as significant proportion of families opt against adjuvant treatment. Although traditionally iMBL considered high risk, good outcomes can be achieved with non-intensified therapy in DN/MBEN subgroup.
- 28 March 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32  (10) , 1319-1326
The BRCA mutation spectrum among breast and ovarian cancers in India: highlighting the need to screen BRCA1 185delAG among South Indians
Mutations in BRCA1 and BRCA2 significantly elevate the risk of developing breast and ovarian cancer. Limited data exists regarding the prevalence of BRCA mutations, and optimal, cost-effective testing strategies in developing countries like India. This study aimed to evaluate the utility of a Next Generation Sequencing (NGS) panel for BRCA1/2 mutation testing among women diagnosed with, or at risk of developing hereditary breast and ovarian cancers. We also aimed to identify population specific BRCA1/2 mutation hotspots, to enable the development of more affordable testing strategies. We identified 921 patients with breast and ovarian cancer who underwent mutation testing. The target enrichment was followed by targeted NGS in 772 patients and an allele-specific PCR (ASPCR) based genotyping for BRCA1:c.68_69delAG (or 185delAG), was carried out in 149 patients. We identified 188 (20.4%) patients with BRCA1/2 variants: 118 (62.8%) with pathogenic/likely pathogenic and 70 (37.2%) with VUS. The 185delAG was identified as a recurrent mutation in the Southern Indian population, accounting for 24.6% of the pathogenic variants. In addition, a family history of breast, ovary, pancreas, or prostate (BOPP) cancer was found to be associated with an increased risk of identifying a deleterious BRCA1/2 variant [OR = 2.11 (95% CI 1.45â3.07) p ⤠0.001]. These results suggest that Targeted NGS is a sensitive and specific strategy for BRCA testing. For Southern Indian patients, a two-tiered approach can be considered: Initial screening with ASPCR for BRCA1 185delAG followed by NGS for those testing negative. Expanding the gene panel and identifying other population-specific mutation hot spots is a promising area with potential for improvements in testing and treatment strategies.
- 28 March 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32  (10) , 1319-1326
The BRCA mutation spectrum among breast and ovarian cancers in India: highlighting the need to screen BRCA1 185delAG among South Indians
Mutations in BRCA1 and BRCA2 significantly elevate the risk of developing breast and ovarian cancer. Limited data exists regarding the prevalence of BRCA mutations, and optimal, cost-effective testing strategies in developing countries like India. This study aimed to evaluate the utility of a Next Generation Sequencing (NGS) panel for BRCA1/2 mutation testing among women diagnosed with, or at risk of developing hereditary breast and ovarian cancers. We also aimed to identify population specific BRCA1/2 mutation hotspots, to enable the development of more affordable testing strategies. We identified 921 patients with breast and ovarian cancer who underwent mutation testing. The target enrichment was followed by targeted NGS in 772 patients and an allele-specific PCR (ASPCR) based genotyping for BRCA1:c.68_69delAG (or 185delAG), was carried out in 149 patients. We identified 188 (20.4%) patients with BRCA1/2 variants: 118 (62.8%) with pathogenic/likely pathogenic and 70 (37.2%) with VUS. The 185delAG was identified as a recurrent mutation in the Southern Indian population, accounting for 24.6% of the pathogenic variants. In addition, a family history of breast, ovary, pancreas, or prostate (BOPP) cancer was found to be associated with an increased risk of identifying a deleterious BRCA1/2 variant [OR = 2.11 (95% CI 1.45â3.07) p ⤠0.001]. These results suggest that Targeted NGS is a sensitive and specific strategy for BRCA testing. For Southern Indian patients, a two-tiered approach can be considered: Initial screening with ASPCR for BRCA1 185delAG followed by NGS for those testing negative. Expanding the gene panel and identifying other population-specific mutation hot spots is a promising area with potential for improvements in testing and treatment strategies.
- Open Access
- 19 July 2023
- Published by Wiley
Pediatric solid pseudopapillary neoplasm of the pancreas.
Background: Solid pseudopapillary neoplasm of the pancreas (SPN) in children is rare tumor with low malignant potential. Some tumors however behave aggressively. There is very little literature on the management of these variants especially in children. We share our experience of managing large and recurrent SPN and explore the clinicopathological findings correlating to the risk of recurrence. Methods: This is a retrospective study of children who were treated for SPN between 2012 and 2022 at a tertiary care center in India. The clinicopathological features and management strategies in these children were evaluated. Results: 16 children with SPN were treated during this period (88% girls). The median age of presentation was 12 years (IQR 9-14). All children presented with abdominal pain. Computed tomography gave a definitive diagnosis in 81% of cases. The tumor predominantly involved the head of the pancreas (n=9, 56%). Eight of nine children classified as high-grade malignant had a benign course. One child had a recurrence of the tumor 4 years after the initial resection and further recurrence on chemotherapy. She required radiation therapy in addition to reoperation following which she is disease free for 77 months. The overall median follow-up was 46 months (IQR 18-72 months). Conclusion: Complete resection of the tumor provides a cure in most patients with SPN. Recurrent tumors require a multi-modality approach. Long-term survival is good. Better prognostic criteria with immunohistochemistry are required to predict the behavior of these tumors as the WHO criteria for malignancy correlate poorly with clinical outcomes in childhood SPN.
- 19 July 2023
- Published by Wiley
Open AccessPediatric solid pseudopapillary neoplasm of the pancreas.
Background: Solid pseudopapillary neoplasm of the pancreas (SPN) in children is rare tumor with low malignant potential. Some tumors however behave aggressively. There is very little literature on the management of these variants especially in children. We share our experience of managing large and recurrent SPN and explore the clinicopathological findings correlating to the risk of recurrence. Methods: This is a retrospective study of children who were treated for SPN between 2012 and 2022 at a tertiary care center in India. The clinicopathological features and management strategies in these children were evaluated. Results: 16 children with SPN were treated during this period (88% girls). The median age of presentation was 12 years (IQR 9-14). All children presented with abdominal pain. Computed tomography gave a definitive diagnosis in 81% of cases. The tumor predominantly involved the head of the pancreas (n=9, 56%). Eight of nine children classified as high-grade malignant had a benign course. One child had a recurrence of the tumor 4 years after the initial resection and further recurrence on chemotherapy. She required radiation therapy in addition to reoperation following which she is disease free for 77 months. The overall median follow-up was 46 months (IQR 18-72 months). Conclusion: Complete resection of the tumor provides a cure in most patients with SPN. Recurrent tumors require a multi-modality approach. Long-term survival is good. Better prognostic criteria with immunohistochemistry are required to predict the behavior of these tumors as the WHO criteria for malignancy correlate poorly with clinical outcomes in childhood SPN.
- 14 July 2023
- Published by Elsevier in World Neurosurgery
- Vol. 178, e189-e201
Correlation Between Post-Radiosurgery Perinidal Hyperintensity and AVM Obliteration Following LINAC-Based Stereotactic Radiosurgery
- 14 July 2023
- Published by Elsevier in World Neurosurgery
- Vol. 178, e189-e201
Correlation Between Post-Radiosurgery Perinidal Hyperintensity and AVM Obliteration Following LINAC-Based Stereotactic Radiosurgery
- 5 May 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37  (9) , e15010
Total marrow lymphoid irradiation and cyclophosphamide is associated with low toxicity and good outcomes in patients undergoing hematopoietic stem cell transplantation for acute lymphoblastic leukemia and chronic myeloid leukemia in lymphoid blast crises â A phase I study
Total marrow lymphoid irradiation (TMLI) can deliver higher doses of irradiation without increasing toxicity compared to Total body irradiation (TBI). Twenty adult patients undergoing hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia with lymphoid blast crises (CML-LBC) received TMLI and cyclophosphamide for conditioning. Ten patients each received 13.5 or 15 Gy of TMLI. The graft source was peripheral blood stem cells in all, and donors included matched related (n = 15), haplo-identical (n = 3) or matched unrelated donors (n = 2). The median cell dose infused was 9 Ă 106 CD34/kg (range 4.8-12.4). Engraftment occurred in all (100%) at a median of 15 days (range: 14-17). Toxicity was low with hemorrhagic cystitis seen in two but no sinusoidal obstruction syndrome. Acute GVHD occurred in 40% while chronic GVHD was seen in 70.5%. Viral infections were seen in 55% while blood stream bacterial infections occurred in 20% and invasive fungal disease (IFD) in 10%. The Day 100 non-relapse mortality (NRM) was 10%. At a median follow up of 25 months (range 2-48), two patients have relapsed. Overall survival at 2 years is 80% while the disease-free survival is 75%. The combination of TMLI and cyclophosphamide for myeloablative conditioning is associated with low toxicity and favorable early outcomes in patients undergoing HSCT for ALL and CML-LBC.
- 5 May 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37  (9) , e15010
Total marrow lymphoid irradiation and cyclophosphamide is associated with low toxicity and good outcomes in patients undergoing hematopoietic stem cell transplantation for acute lymphoblastic leukemia and chronic myeloid leukemia in lymphoid blast crises â A phase I study
Total marrow lymphoid irradiation (TMLI) can deliver higher doses of irradiation without increasing toxicity compared to Total body irradiation (TBI). Twenty adult patients undergoing hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia with lymphoid blast crises (CML-LBC) received TMLI and cyclophosphamide for conditioning. Ten patients each received 13.5 or 15 Gy of TMLI. The graft source was peripheral blood stem cells in all, and donors included matched related (n = 15), haplo-identical (n = 3) or matched unrelated donors (n = 2). The median cell dose infused was 9 Ă 106 CD34/kg (range 4.8-12.4). Engraftment occurred in all (100%) at a median of 15 days (range: 14-17). Toxicity was low with hemorrhagic cystitis seen in two but no sinusoidal obstruction syndrome. Acute GVHD occurred in 40% while chronic GVHD was seen in 70.5%. Viral infections were seen in 55% while blood stream bacterial infections occurred in 20% and invasive fungal disease (IFD) in 10%. The Day 100 non-relapse mortality (NRM) was 10%. At a median follow up of 25 months (range 2-48), two patients have relapsed. Overall survival at 2 years is 80% while the disease-free survival is 75%. The combination of TMLI and cyclophosphamide for myeloablative conditioning is associated with low toxicity and favorable early outcomes in patients undergoing HSCT for ALL and CML-LBC.
- 1 December 2021
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 20  (4) , 426-432
Long-term outcomes of patients with primary or residual vestibular schwannoma treated with LINAC-based stereotactic radiosurgery: a single-centre experience
Aim: Vestibular schwannomas (VS) are benign slow-growing tumours treated either with microsurgery or stereotactic radiosurgery (SRS) or both. The aim of this study was to correlate the outcome factors-tumour control and adverse factors-facial nerve function and hearing loss with patient and treatment factors. Materials and methods: A retrospective review of the records of 98 patients with 99 VS treated from June 2007 to June 2014, all patients receiving Linear Accelerator (LINAC)-based SRS. Results: Median follow-up period was 5.6 years (range: 1-12 years). The response to treatment was stable disease in 37 (37.4%), regression in 46 (46.5%), asymptomatic minimal progression in 9 (9.1%) and symptomatic progression in 5 (5%) and unknown in 2 (2%) patients. There was no evidence of SRS induced tissue damage on magnetic resonance scans for any. Hearing preservation rate after SRS was 92%. The patients who developed worsening of facial function were predominantly in the cohort that had prior surgery. Findings: SRS is an effective modality to treat VS lesser than 3 cm in size. Tumour control rate was 95% with a median follow-up period of 5.6 years. The complication rates were 8% each for facial function worsening and worsening of hearing. Prior surgery was a statistically significant factor that affected facial nerve function deterioration.
- 1 December 2021
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 20  (4) , 426-432
Long-term outcomes of patients with primary or residual vestibular schwannoma treated with LINAC-based stereotactic radiosurgery: a single-centre experience
Aim: Vestibular schwannomas (VS) are benign slow-growing tumours treated either with microsurgery or stereotactic radiosurgery (SRS) or both. The aim of this study was to correlate the outcome factors-tumour control and adverse factors-facial nerve function and hearing loss with patient and treatment factors. Materials and methods: A retrospective review of the records of 98 patients with 99 VS treated from June 2007 to June 2014, all patients receiving Linear Accelerator (LINAC)-based SRS. Results: Median follow-up period was 5.6 years (range: 1-12 years). The response to treatment was stable disease in 37 (37.4%), regression in 46 (46.5%), asymptomatic minimal progression in 9 (9.1%) and symptomatic progression in 5 (5%) and unknown in 2 (2%) patients. There was no evidence of SRS induced tissue damage on magnetic resonance scans for any. Hearing preservation rate after SRS was 92%. The patients who developed worsening of facial function were predominantly in the cohort that had prior surgery. Findings: SRS is an effective modality to treat VS lesser than 3 cm in size. Tumour control rate was 95% with a median follow-up period of 5.6 years. The complication rates were 8% each for facial function worsening and worsening of hearing. Prior surgery was a statistically significant factor that affected facial nerve function deterioration.
- Open Access
- 22 November 2021
- Published by Taylor & Francis in CNS Oncology
- Vol. 10  (4) , CNS79
A pragmatic diagnostic approach to primary intracranial germ cell tumors and their treatment outcomes
Background: Primary intracranial germ cell tumors (ICGCT) are often diagnosed with tumor markers and imaging, which may avoid the need for a biopsy. An intracranial germ cell tumor with mild elevat... Lay abstract Intracranial germ cell tumors (ICGCTs) are rare brain tumors, which often require markers in blood or cerebrospinal fluid, imaging and a tissue biopsy to establish a diagnosis. However... Tweetable abstract Central nervous system germinomas can often be diagnosed with tumor markers and imaging, and they may not always need a biopsy. A criterion for clinical diagnosis is elucidated i...
- 22 November 2021
- Published by Taylor & Francis in CNS Oncology
- Vol. 10  (4) , CNS79
Open AccessA pragmatic diagnostic approach to primary intracranial germ cell tumors and their treatment outcomes
Background: Primary intracranial germ cell tumors (ICGCT) are often diagnosed with tumor markers and imaging, which may avoid the need for a biopsy. An intracranial germ cell tumor with mild elevat... Lay abstract Intracranial germ cell tumors (ICGCTs) are rare brain tumors, which often require markers in blood or cerebrospinal fluid, imaging and a tissue biopsy to establish a diagnosis. However... Tweetable abstract Central nervous system germinomas can often be diagnosed with tumor markers and imaging, and they may not always need a biopsy. A criterion for clinical diagnosis is elucidated i...